Westover v. Metropolitan Life Ins. Co., 89-1458-Civ-T-20(C).
Decision Date | 10 September 1991 |
Docket Number | No. 89-1458-Civ-T-20(C).,89-1458-Civ-T-20(C). |
Citation | 771 F. Supp. 1172 |
Parties | Stanley WESTOVER, Plaintiff, v. METROPOLITAN LIFE INSURANCE COMPANY, Defendant. |
Court | U.S. District Court — Middle District of Florida |
James A. Sheehan, St. Petersburg, Fla., for plaintiff.
Frances G. Fernandez, Tampa, Fla., for defendant.
This matter is before the Court for decision following the trial of the Plaintiff's claim for medical benefits. This Court has jurisdiction pursuant to the Employee Retirement Income Security Act ("ERISA"), 29 U.S.C. §§ 1001-1461.
The Court has considered the pleadings, the testimony of the witnesses, the documents and other evidence of record, and the parties' briefs in making the following findings of fact and conclusions of law.
1. The Plaintiff was a covered beneficiary under the Southeast Banking Company employee health plan ("Southeast Plan").
2. Metropolitan Life Insurance Company ("Met Life") was employed by Southeast Banking Company for the purpose of claims review and decision making.
3. Beginning in August 1986, the Plaintiff sought and received chelation therapy treatments for the treatment of his arteriosclerosis.
4. In September 1986 and October 1986, the Plaintiff submitted claims for medical benefits for the chelation therapy treatments which he had sought and received for his arteriosclerosis.
5. Upon discovering that the claims submitted were for chelation therapy for the treatment of arteriosclerosis, the claims were denied in reliance upon the following provisions of the Southeast Plan:
and:
Defendant's Exhibit No. 2, pp. 22-25.
Thus, Met Life denied the claim for benefits on the grounds that the treatment for which the Plaintiff sought reimbursement was experimental in terms of generally accepted medical standards.
6. Prior to issuing its denial of the Plaintiff's claim, Met Life examined the purpose for the treatment, the specific treatment proposed, the current medical and governmental opinion regarding the status and efficacy of chelation therapy for the treatment of arteriosclerosis.
7. The state of generally accepted medical and governmental opinion at all times material to this case was that chelation therapy for the treatment of arteriosclerosis was experimental and that the therapeutic effectiveness, indications for use, optimum doses, complications and long term effectiveness had not yet been conclusively established. In August 1989, three years after the Plaintiff first received chelation therapy for his arteriosclerosis, the Food and Drug Administration stated that:
its safety is questioned and its clinical effectiveness has never been established by well designed, controlled clinical trials. It is not widely accepted and practiced by American physicians. EDTA chelation therapy for atherosclerosis is considered experimental.
1. The Southeast Plan is an "employee welfare plan" as that term is defined in 29 U.S.C. § 1002(1). As such, this case is controlled in its entirety by the Employee Retirement Income Security Act, 29 U.S.C. §§ 1001-1461. This Court has jurisdiction pursuant to 29 U.S.C. § 1132(a)(1)(B).
2. As this matter involves an employee welfare benefit plan governed by ERISA, all state laws are pre-empted.
3. The Notices section of the Southeast Plan states that Met Life will:
Defendant's Exhibit No. 2, p. 42.
By virtue of this provision, the Southeast Plan gives Met Life the discretionary authority to determine eligibility for benefits. Therefore, the decision to deny benefits in this case should be upheld unless arbitrary and capricious. Firestone Tire & Rubber Co. v. Bruch, 489 U.S. 101, 109 S.Ct. 948, 103 L.Ed.2d 80 (1989); Jett v. Blue Cross and Blue Shield of Alabama, 890 F.2d 1137 (11th Cir.1989).
4. The Plaintiff's reliance on Rogers v. State Bd. Of Med. Examiners, 371 So.2d 1037 (Fla.App.1979), aff'd, 387 So.2d 937 (Fla.1980) is misplaced. The issue in Rogers concerned the extent of the State of Florida's constitutional authority to prohibit a non-harmful mode of medical treatment by a licensed physician after full disclosure to, and election by, a patient. The issue in the instant case is whether chelation therapy is covered under the Southeast Plan. In resolving that issue, the Court is required to determine who is charged under the contract with making the decision whether a particular procedure is covered. Since Defendant Met Life must make that decision, the Court will uphold it unless arbitrary and capricious.
5. The decision to deny...
To continue reading
Request your trial-
Fitts v. Federal Nat. Mortg. Ass'n
...Plan gives the Committee the right to review the disposition of claims for benefits. See Plan at 15; cf. Westover v. Metropolitan Life Ins. Co., 771 F.Supp. 1172, 1174 (M.D.Fla.1991) (administrator had discretion where plan authorized it to "make the decision as to whether such service is m......
-
Heasley v. Belden & Blake Corp.
...(plan provided "The Company shall determine the eligibility of a person for benefits under the plan"); Westover v. Metropolitan Life Ins. Co., 771 F.Supp. 1172, 1174 (M.D.Fla.1991) (plan provided Claims administrator Met Life "will make the decision as to whether such service is medically n......
-
Sharp v. Kmart Corp.
... ... Deere & Co. In Hensgens, the Fifth Circuit found that ... In Burka v. Aetna Life Ins. Co., 42 the court found that defendants' ... ...
-
Friends Hosp. v. Metrahealth Service Corp.
...are needed which grants discretion and warrants application of arbitrary and capricious standard); Westover v. Metropolitan Life Insurance Company, 771 F.Supp. 1172 (M.D.Fl.1991)(definition of covered services includes those that are medically necessary which grants discretion sufficient to......